Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Robert James Mayer, M.D.

Co-Author

This page shows the publications co-authored by Robert Mayer and Jeffrey Meyerhardt.
Connection Strength

3.731
  1. Systemic therapy for colorectal cancer. N Engl J Med. 2005 Feb 03; 352(5):476-87.
    View in: PubMed
    Score: 0.303
  2. Follow-up strategies after curative resection of colorectal cancer. Semin Oncol. 2003 Jun; 30(3):349-60.
    View in: PubMed
    Score: 0.270
  3. Age and comorbidity association with survival outcomes in metastatic colorectal cancer: CALGB 80405 analysis. J Geriatr Oncol. 2022 Jan 29.
    View in: PubMed
    Score: 0.246
  4. Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405. J Clin Oncol. 2019 10 10; 37(29):2620-2631.
    View in: PubMed
    Score: 0.207
  5. Grain Intake and Clinical Outcome in Stage III Colon Cancer: Results From CALGB 89803 (Alliance). JNCI Cancer Spectr. 2018 Feb; 2(2):pky017.
    View in: PubMed
    Score: 0.191
  6. Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance). J Clin Oncol. 2017 Nov 10; 35(32):3671-3677.
    View in: PubMed
    Score: 0.182
  7. Sugar-sweetened beverage intake and cancer recurrence and survival in CALGB 89803 (Alliance). PLoS One. 2014; 9(6):e99816.
    View in: PubMed
    Score: 0.145
  8. Impact of physical activity after cancer diagnosis on survival in patients with recurrent colon cancer: Findings from CALGB 89803/Alliance. Clin Colorectal Cancer. 2013 Dec; 12(4):233-8.
    View in: PubMed
    Score: 0.138
  9. Dietary glycemic load and cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Natl Cancer Inst. 2012 Nov 21; 104(22):1702-11.
    View in: PubMed
    Score: 0.130
  10. Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803. J Clin Oncol. 2008 Sep 01; 26(25):4109-15.
    View in: PubMed
    Score: 0.097
  11. The impact of smoking on cancer recurrence and survival in patients with stage III colon cancer: Findings from intergroup trial CALGB 89803. J Clin Oncol. 2008 May 20; 26(15_suppl):4039.
    View in: PubMed
    Score: 0.095
  12. Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. JAMA. 2007 Aug 15; 298(7):754-64.
    View in: PubMed
    Score: 0.090
  13. Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancer. Ann Oncol. 2007 Jul; 18(7):1185-9.
    View in: PubMed
    Score: 0.089
  14. Adjuvant treatment of colorectal cancer. CA Cancer J Clin. 2007 May-Jun; 57(3):168-85.
    View in: PubMed
    Score: 0.088
  15. Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. Cancer Chemother Pharmacol. 2007 Oct; 60(5):661-70.
    View in: PubMed
    Score: 0.087
  16. Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol. 2006 Aug 01; 24(22):3535-41.
    View in: PubMed
    Score: 0.084
  17. The impact of physical activity on patients with stage III colon cancer: Findings from Intergroup trial CALGB 89803. J Clin Oncol. 2005 Jun; 23(16_suppl):3534.
    View in: PubMed
    Score: 0.077
  18. Influence of regular aspirin use on survival for patients with stage III colon cancer: Findings from Intergroup trial CALGB 89803. J Clin Oncol. 2005 Jun; 23(16_suppl):3530.
    View in: PubMed
    Score: 0.077
  19. Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114. J Clin Oncol. 2004 Feb 15; 22(4):648-57.
    View in: PubMed
    Score: 0.071
  20. Impact of hospital procedure volume on surgical operation and long-term outcomes in high-risk curatively resected rectal cancer: findings from the Intergroup 0114 Study. J Clin Oncol. 2004 Jan 01; 22(1):166-74.
    View in: PubMed
    Score: 0.070
  21. Association of hospital procedure volume and outcomes in patients with colon cancer at high risk for recurrence. Ann Intern Med. 2003 Oct 21; 139(8):649-57.
    View in: PubMed
    Score: 0.069
  22. Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma. Cancer. 2003 Aug 01; 98(3):484-95.
    View in: PubMed
    Score: 0.068
  23. Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol. 2003 Feb 01; 21(3):433-40.
    View in: PubMed
    Score: 0.066
  24. Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405. J Natl Cancer Inst. 2022 03 08; 114(3):427-435.
    View in: PubMed
    Score: 0.062
  25. Plasma 25-Hydroxyvitamin D Levels and Survival in Patients with Advanced or Metastatic Colorectal Cancer: Findings from CALGB/SWOG 80405 (Alliance). Clin Cancer Res. 2019 12 15; 25(24):7497-7505.
    View in: PubMed
    Score: 0.052
  26. Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial. Eur J Cancer. 2019 04; 111:82-93.
    View in: PubMed
    Score: 0.050
  27. Dietary Insulin Load and Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803 (Alliance). J Natl Cancer Inst. 2019 02 01; 111(2):170-179.
    View in: PubMed
    Score: 0.050
  28. Associations of artificially sweetened beverage intake with disease recurrence and mortality in stage III colon cancer: Results from CALGB 89803 (Alliance). PLoS One. 2018; 13(7):e0199244.
    View in: PubMed
    Score: 0.048
  29. Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. Cancer Discov. 2018 09; 8(9):1096-1111.
    View in: PubMed
    Score: 0.048
  30. Nut Consumption and Survival in Patients With Stage III Colon Cancer: Results From CALGB 89803 (Alliance). J Clin Oncol. 2018 04 10; 36(11):1112-1120.
    View in: PubMed
    Score: 0.047
  31. Predicted vitamin D status and colon cancer recurrence and mortality in CALGB 89803 (Alliance). Ann Oncol. 2017 Jun 01; 28(6):1359-1367.
    View in: PubMed
    Score: 0.045
  32. Development and Validation of the PREMM5 Model for Comprehensive Risk Assessment of Lynch Syndrome. J Clin Oncol. 2017 Jul 01; 35(19):2165-2172.
    View in: PubMed
    Score: 0.044
  33. Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer. J Clin Oncol. 2017 Apr 01; 35(10):1086-1095.
    View in: PubMed
    Score: 0.043
  34. Coffee Intake, Recurrence, and Mortality in Stage III Colon Cancer: Results From CALGB 89803 (Alliance). J Clin Oncol. 2015 Nov 01; 33(31):3598-607.
    View in: PubMed
    Score: 0.039
  35. Aspirin and COX-2 inhibitor use in patients with stage III colon cancer. J Natl Cancer Inst. 2015 Jan; 107(1):345.
    View in: PubMed
    Score: 0.037
  36. Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. J Natl Cancer Inst. 2013 Dec 04; 105(23):1789-98.
    View in: PubMed
    Score: 0.035
  37. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res. 2012 Feb 01; 18(3):890-900.
    View in: PubMed
    Score: 0.030
  38. Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803. J Natl Cancer Inst. 2011 Oct 19; 103(20):1540-51.
    View in: PubMed
    Score: 0.030
  39. Multivitamin use is not associated with cancer recurrence or survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol. 2010 Oct 01; 28(28):4354-63.
    View in: PubMed
    Score: 0.028
  40. KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res. 2009 Dec 01; 15(23):7322-9.
    View in: PubMed
    Score: 0.026
  41. KRAS mutation, cancer recurrence, and patient survival in stage III colon cancer: Findings from CALGB 89803. J Clin Oncol. 2009 May 20; 27(15_suppl):4037.
    View in: PubMed
    Score: 0.026
  42. Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer. Ann Oncol. 2009 Mar; 20(3):475-80.
    View in: PubMed
    Score: 0.025
  43. Association of family history with cancer recurrence and survival among patients with stage III colon cancer. JAMA. 2008 Jun 04; 299(21):2515-23.
    View in: PubMed
    Score: 0.024
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.